| Nov 1 |
MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run?
|
| Oct 31 |
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
|
| Oct 31 |
First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
|
| Oct 9 |
MannKind Corp (MNKD) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Pipeline ...
|
| Oct 9 |
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
|
| Oct 7 |
Why MannKind (MNKD) Could Beat Earnings Estimates Again
|
| Oct 4 |
Exploring High Growth Tech Stocks In The United States October 2024
|
| Oct 4 |
MannKind (MNKD) Just Overtook the 20-Day Moving Average
|
| Oct 3 |
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
|
| Sep 30 |
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
|
